ロード中...
Histone deacetylation, as opposed to promoter methylation, results in epigenetic BIM silencing and resistance to EGFR TKI in NSCLC
Drug resistance remains a major challenge in epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy. Bcl-2-like protein 11 (BIM), a B-cell lymphoma 2 family pro-apoptotic protein, is a prime target for specific anti-cancer therapeutics. However, the epigenetic regulation of BI...
保存先:
| 出版年: | Oncol Lett |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
D.A. Spandidos
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5772734/ https://ncbi.nlm.nih.gov/pubmed/29399169 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.7411 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|